Occlude Defect ,
To provide global doctors and patients with safe and innovate medical devices to treat cardiovascular diseases
Being an innovative company, we consistently explore new idea and methods
27th January 2021, LifeTech Scientific Corporation obtained formal written notice from the National Medical Products Administration confirming the admission of Artery Stent Graft System into the NMPA Special Examination and Approval Procedure for Innovative Medical Services.
On 13 January 2021, G-iliac? iliac artery bifurcation stent graft system, the novel device self-developed by LifeTech Scientific Corporation,has obtained the market registration approval from the China National Medical Products Administration.
On 24 December 2020, LAmbre?Left Atrial Appendage Closure System,developed by LifeTech Scientific Corporation,has obtained the approval by the US Food and Drug Administration for the commencement of an investigator-initiated clinical trial in the US.
LifeTech Scientific Corporation (the “Company” or “Lifetech”), a?leading company specialized in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, today announced the unaudited consolidated results of the Company and its subsidiaries (collectively the “Group”) for the six months ended 30 June 2023 (the “Reporting Period”).
LifeTech Scientific Corporation (the “Company” or “Lifetech”), a?leading company specialized in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, today announced its 2022 annual results.
LifeTech Scientific Corporation (Stock Code: 1302.HK) is pleased to announce that on 30 August 2022, an FDA-approved investigator-initiated pre-market clinical trial of its proprietary LAmbre? Plus Left Atrial Appendage (LAA) Closure System has obtained medical insurance coverage in the United States
Lifetech is a leading developer, manufacturer and vendor of advanced minimally invasive medical devices for cardiovascular and peripheral vascular diseases and disorders.
Founded in 1999, we are now the second largest provider of congenital heart defect occluders in the world and the largest provider to BRIC countries.